26 June 2025 Biotech institute successfully challenges EPO decision revoking key CRISPR patent over priority rights | Appeal follows major changes to European law | Case returns to lower court for novelty and inventive step evaluation.
Latest Features
Europe
Despite efforts to harmonise, the Unified Patent Court’s local divisions and Court of Appeal have signalled a divergence over implementing the European Patent Convention—but does it matter? Chris Moore and Hsu Min Chung of HGF report.
Europe
Two years since the UPC opened its doors, various developments might influence the UK government to reassess its position, write Amanda Ebbutt and Paul England of Taylor Wessing.
Europe
A new law affecting disputes concerning the ‘Bolar provision’ could allow competitors to enter the Ukrainian market before a patent expires, explains Volodymyr Hrunskyi of Sayenko Kharenko.
Africa
Genomic innovations involve vast amounts of research, making patents, copyrights, and trade secrets vital, explains Olusola Tunmise-Ajani of Inventa International.
Europe
Following the Unified Patent Court’s recent Meril v Edwards decision, Agathe Michel-de Cazotte & Ben Chapman of Carpmaels & Ransford examine the court’s treatment of obviousness to date.
Europe
For those willing to undertake the complexity, in vivo cell therapy could redefine the economics and logistics of cell-based treatment, says Adam Gregory of Mewburn Ellis.
Europe
Supplementary Protection Certificate rules interpreted in different ways have left the EU’s generic and biosimilar industries hungry for clarity, explains Jiri Slavik of Adalvo.
Unified Patent Court
The UPC Court of Appeal’s approach to delivering a preliminary injunction in a glucose sensor dispute has far-reaching effects, as Wouter Pors of Bird & Bird explains.
More News
23 June 2025 David Gindler of Orrick discusses the US Supreme Court’s ruling in Amgen v Sanofi and what it means for ongoing Section 112 litigation. The session considers how the decision has been applied—and how it may continue to be applied—by the Federal Circuit, district courts, and the PTAB, with a focus on its relevance to the life sciences sector.
20 June 2025 Court sets strict rules on rehearing's, saying "only fundamental procedural defects can be the basis for a rehearing” | Follows UK blow to Alexion, allowing biosimilars onto market.
19 June 2025 Regeneron files motion to disqualify firm from patent and antitrust dispute | Motion cites conflict of interest due to Kirkland’s prior work for Regeneron | Kirkland denies conflict, citing screening measures.
19 June 2025 The biotech firm strikes again over Eylea after Amgen launches biosimilar | Regeneron claims Amgen infringed agreed ‘patent dance’ | Follows other lawsuits aimed at protecting Eylea.
19 June 2025 Former in-house counsel at major pharma companies brings expertise in IP strategy, regulatory compliance, and business development across pharma and biotech.
17 June 2025 Court affirms infringement of patent covering gene expression technology | Curio Bioscience cannot sell related products in three EU countries | Decision is “further testament to 10x Genomic’s strategic use of IP”, 10x counsel tells LSIPR.
17 June 2025 Semaglutide generics set to enter the Canadian market by 2026 after Novo Nordisk failed to maintain key patent | Speculation over whether it was a mistake or calculated move in a country known for strict drug price controls.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox